Understanding the causes of recurring venous thromboembolic disease
Prospective Cohort Study on the Determinants of Venous THromboembolic Recurrence. BREIZH-Cohorte
This study is trying to find out why some people under 50 and cancer patients keep having blood clots and what might increase their chances of getting them again.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 3400 (estimated) |
| Sex | All |
| Sponsor | University Hospital, Brest Academic / other |
| Locations | 4 sites (Brest and 3 other locations) |
| Trial ID | NCT04297085 on ClinicalTrials.gov |
What this trial studies
This study aims to assess the incidence of recurrent thromboembolic venous disease and identify risk factors for recurrence in two specific groups: individuals under 50 years old and cancer patients. It focuses on the serious complications associated with deep vein thrombosis (DVT) and pulmonary embolism (PE), which can lead to significant mortality and long-term health issues. Participants will provide biological samples to aid in the research. The study is conducted at the University Hospital in Brest, France.
Who should consider this trial
Good fit: Ideal candidates include individuals aged 18 and over with a diagnosis of thromboembolic venous disease, particularly those under 50 or any age with active cancer.
Not a fit: Patients who are foreign nationals or unable to communicate effectively may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved understanding and management of thromboembolic venous disease, potentially reducing recurrence rates and associated complications.
How similar studies have performed: Other studies have shown success in understanding thromboembolic disease, but this specific cohort approach focusing on age and cancer status is relatively novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Subject aged 18 or over, or a minor with the consent of the parents and the minor, presenting with a thromboembolic venous disease * 50 and under or any age if active cancer * Affiliated to social security * Accepting to participate in the study. Exclusion Criteria: * Inability to communicate (comprehension disorder). * Refusal to participate.
Where this trial is running
Brest and 3 other locations
- CHRU Brest — Brest, France (Recruiting)
- HIA Clermont Tonnerre Brest — Brest, France (Recruiting)
- CH Morlaix — Morlaix, France (Recruiting)
- CH de Cornouaille — Quimper, France (Recruiting)
Study contacts
- Principal investigator: Francis COUTURAUD, MD, PHD — EA3878 (GETBO), Brest University Hospital in France
- Study coordinator: Francis COUTURAUD, MD, PHD
- Email: francis.couturaud@chu-brest.fr
- Phone: 02 98 34 73 47
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.